| Invion Receives $0.5m R&D Tax Incentive Rebate | Nov 18, 2026 | Results | ASX |
|---|
| Change of Director's Interest Notice - Thian Chew | Nov 17, 2026 | Ownership change notice | ASX |
|---|
| Notification of cessation of securities - IVX | Nov 17, 2026 | Financing | ASX |
|---|
| IVX Director Appointment/Resignation & New Company Secretary | Nov 10, 2026 | Management or board change | ASX |
|---|
| Appendix 4C and Quarterly Activities Report - September 2026 | Oct 28, 2026 | Quarterly report | ASX |
|---|
| Notice of Annual General Meeting/Proxy Form | Oct 23, 2026 | Meeting notice | ASX |
|---|
| Proposed issue of securities - IVX | Oct 20, 2026 | Financing | ASX |
|---|
| Funding Agreements Cover Up to 85% of Clinical Trials Costs | Oct 20, 2026 | Financing | ASX |
|---|
| Funding Agreements Cover Up to 85% of Clinical Trials Costs | Oct 20, 2026 | Financing | ASX |
|---|
| Photosoft & Novel Immunotherapy Collab Partnership | Oct 19, 2026 | Other filings | ASX |
|---|
| PER: Percheron and Invion Explore Cancer Combination Therapy | Oct 19, 2026 | Other filings | ASX |
|---|
| Recruitment Conclusion for Ph 1 NMSC Trial & Advance to Ph 2 | Oct 18, 2026 | Operations update | ASX |
|---|
| Application for quotation of securities - IVX | Oct 15, 2026 | Financing | ASX |
|---|
| Proposed issue of securities - IVX | Sep 29, 2026 | Financing | ASX |
|---|
| Director Loans | Sep 29, 2026 | Financing | ASX |
|---|
| Appendix 4G and Corporate Governance Statement | Aug 26, 2026 | Annual report | ASX |
|---|
| Appendix 4E and Annual Report | Aug 26, 2026 | Annual report | ASX |
|---|
| Initial Director's Interest Notice - Paul FIeld | Aug 20, 2026 | Ownership change notice | ASX |
|---|
| Final Director's Interest Notice - Alistair Bennallack | Aug 20, 2026 | Ownership change notice | ASX |
|---|
| IVX Credentialed International Biotech Leader Joins Board | Aug 18, 2026 | Management or board change | ASX |
|---|
| Appendix 4C and Quarterly Activities Report - June 2026 | Jul 30, 2026 | Quarterly report | ASX |
|---|
| Photosoft Platform Expands to Eye Diseases Via Partnership | May 18, 2026 | Operations update | ASX |
|---|
| Appendix 4C and Quarterly Activities Report - March 2026 | Apr 30, 2026 | Quarterly report | ASX |
|---|
| Skin Cancer Trial Moves to BCC With More Encouraging Signals | Apr 21, 2026 | Operations update | ASX |
|---|
| Appendix 4D and Half Year Financial Report | Feb 26, 2026 | Interim report | ASX |
|---|
| Appendix 4C and Quarterly Activities Report - December 2025 | Jan 30, 2026 | Quarterly report | ASX |
|---|
| Major Shareholders Lead Invion $1.3M Capital Raise | Jan 30, 2026 | Financing | ASX |
|---|
| Trading Halt | Jan 28, 2026 | Trading halt or suspension | ASX |
|---|
| Pause in Trading | Jan 28, 2026 | Trading halt or suspension | ASX |
|---|
| Hanlim & Korean Government Fund Pathway to Clinical Trial | Dec 22, 2025 | Financing | ASX |
|---|
| Invion Secures Expanded Photosoft Global Exclusive License | Dec 2, 2025 | Acquisition or disposal | ASX |
|---|
| Appendix 4C and Quarterly Activities Report - September 2025 | Oct 30, 2025 | Quarterly report | ASX |
|---|
| Funded Collaboration Agreement with Protect Animal Health | Oct 20, 2025 | Operations update | ASX |
|---|
| Repayment of Lind Facility with Successful Capital Raise | Oct 9, 2025 | Financing | ASX |
|---|
| Response to ASX Aware Letter | Aug 27, 2025 | Explanation request | ASX |
|---|
| Appendix 4E and Annual Report | Aug 27, 2025 | Annual report | ASX |
|---|
| Response to ASX Price Query | Aug 20, 2025 | Explanation request | ASX |
|---|
| Orphan Drug Designation Granted by U.S. FDA For Anal Cancer | Aug 20, 2025 | Other filings | ASX |
|---|
| Appendix 4C and Quarterly Activities Report - June 2025 | Jul 31, 2025 | Quarterly report | ASX |
|---|
| Security Class Reinstatement to Quotation | Jul 17, 2025 | Trading halt or suspension | ASX |
|---|
| Security Class Suspension from Quotation | Jul 10, 2025 | Trading halt or suspension | ASX |
|---|
| Underwritten Loyalty Option Entitlement Offer Prospectus | Jun 23, 2025 | Offer document | ASX |
|---|
| EQR Progresses Regional Tungsten Hub Strategy | Jun 13, 2025 | Other filings | ASX |
|---|
| Loyalty Option Entitlement Offer | Jun 13, 2025 | Financing | ASX |
|---|
| Encouraging SRC Findings on Ph I/II Skin Cancer Trial | May 28, 2025 | Operations update | ASX |
|---|
| Dosing of 1st Six Patients in Phase I/II Skin Cancer Trial | May 1, 2025 | Operations update | ASX |
|---|
| Appendix 4C and Quarterly Activities Report - March 2025 | Apr 30, 2025 | Quarterly report | ASX |
|---|
| Share Purchase Agreement Termination and Tranche Repayment | Mar 4, 2025 | Other filings | ASX |
|---|
| Completion Of Placement to Accelerate Clinical Programs | Mar 4, 2025 | Financing | ASX |
|---|
| Oesophageal Cancer Collaboration and Funding Agreement | Feb 25, 2025 | Operations update | ASX |
|---|
| Activities Report and Appendix 4C | Jan 30, 2025 | Quarterly report | ASX |
|---|
| Invion Doses First Patient in Phase I/II Skin Cancer Trial | Dec 2, 2024 | Other filings | ASX |
|---|
| Consolidation/Split - IVX | Oct 14, 2024 | Other filings | ASX |
|---|
| Ph 2 Prostate Cancer Results Strong Safety and 40% Response | Sep 17, 2024 | Other filings | ASX |
|---|
| Invion secures funding through an institutional placement | Jun 27, 2024 | Financing | ASX |
|---|
| Agreement with Major South Korean Pharma Group Hanlim | May 7, 2024 | Operations update | ASX |
|---|
| INV043 With ICI Therapy Achieved 80% Tumour Control For ASCC | Mar 4, 2024 | Operations update | ASX |
|---|
| Agreement with Dr.inB to develop Photosoft treatment for HPV | Feb 22, 2024 | Operations update | ASX |
|---|
| AGM Presentation | Nov 28, 2023 | Other filings | ASX |
|---|
| Major Milestone towards Clinical Trials | Nov 21, 2023 | Other filings | ASX |
|---|
| Investor Presentation | Oct 23, 2023 | Other filings | ASX |
|---|
| Photosoft Territory Expanded to South Korea for Cancer | Sep 24, 2023 | Operations update | ASX |
|---|
| Appendix 4E and Preliminary Financial Report | Aug 30, 2023 | Results | ASX |
|---|
| Expansion of Territory Rights to USA, Canada and Hong Kong | Feb 7, 2023 | Other filings | ASX |
|---|
| INV043 Effective Against Anal Cancer SCC In Vitro | Sep 14, 2022 | Other filings | ASX |
|---|
| Response to ASX Aware Query | Sep 13, 2022 | Explanation request | ASX |
|---|
| Photosoft Shows Activity Against Zika Virus | Sep 7, 2022 | Other filings | ASX |
|---|
| INV043 SIGNIFICANTLY IMPROVED CHECKPOINT INHIBITOR THERAPY | May 29, 2022 | Other filings | ASX |
|---|
| Supplementary Prospectus | Nov 25, 2021 | Offer document | ASX |
|---|
| Prospectus | Nov 22, 2021 | Offer document | ASX |
|---|
| Share Purchase Plan Offer Booklet & Application Form | Nov 21, 2021 | Financing | ASX |
|---|
| Capital Raising and expansion of Photosoft Territory | Nov 16, 2021 | Financing | ASX |
|---|
| Further Information on Proof of Concept Pilot Study | Oct 28, 2021 | Other filings | ASX |
|---|
| Complete Regression of TNBC Tumours and Protective Immunity | Oct 27, 2021 | Other filings | ASX |
|---|
| Capital Raising & co-development for Photosoft Technology | Jun 2, 2021 | Financing | ASX |
|---|
| Initial Proof-of-Concept results show INV043 to be effective | May 24, 2021 | Other filings | ASX |
|---|
| App 4D and Financial Report for half year to 31 Dec 2020 | Feb 24, 2021 | Other filings | ASX |
|---|
| Business Update and Change to Board and Management | Jul 28, 2020 | Operations update | ASX |
|---|
| Activities Report and Appendix 4C June 2020 Quarter | Jul 28, 2020 | Quarterly report | ASX |
|---|
| Invion subsidiary signs Supply Agreement with Pavay Biotech | Jun 30, 2020 | Other filings | ASX |
|---|
| Appendix 4C - March 2020 quarter | Apr 20, 2020 | Quarterly report | ASX |
|---|
| App 4D and Financial Report for half year to 31 Dec 2019 | Feb 24, 2020 | Other filings | ASX |
|---|
| Invion signs R&D Services Agreement with Pavay Biotech | Feb 2, 2020 | Other filings | ASX |
|---|
| Appendix 4C - December 2019 quarter | Jan 29, 2020 | Quarterly report | ASX |
|---|
| Additional Information to Prior Announcement | Nov 28, 2019 | Other filings | ASX |
|---|
| Pre-clinical research agreement with Peter MacCallum CC | Oct 30, 2019 | Other filings | ASX |
|---|
| Appendix 4C - September 2019 quarter | Oct 28, 2019 | Quarterly report | ASX |
|---|
| Appendix 4E and Financial Report for year ended 30 June 2019 | Aug 28, 2019 | Results | ASX |
|---|
| COO Craig Newton to transition to Invion CEO | Jul 21, 2019 | Other filings | ASX |
|---|
| Appendix 4C - June quarter | Jul 12, 2019 | Quarterly report | ASX |
|---|
| Animal studies show IVX-P02 potential in metastatic cancers | May 27, 2019 | Other filings | ASX |
|---|
| Quarterly Update | Apr 17, 2019 | Other filings | ASX |
|---|
| Appendix 4D and Financial Report for Half Year to 31 Dec 18 | Feb 26, 2019 | Interim report | ASX |
|---|
| Response to ASX Appendix 4C Query | Feb 20, 2019 | Explanation request | ASX |
|---|
| Invion completes spin-out of respiratory assets | Feb 11, 2019 | Other filings | ASX |
|---|
| General Meeting - Results of Meeting | Jan 30, 2019 | Meeting outcome | ASX |
|---|
| Appendix 4C - December quarter | Jan 28, 2019 | Quarterly report | ASX |
|---|
| Appendix 4C - September 2018 quarter | Oct 28, 2018 | Quarterly report | ASX |
|---|
| New Photosoft formulation increased effect in ovarian cancer | Sep 24, 2018 | Other filings | ASX |
|---|
| Spin out of respiratory assets for development in China | Sep 4, 2018 | Other filings | ASX |
|---|
| Appendix 4E Annual Report and Full Year Statutory Accounts | Aug 28, 2018 | Annual report | ASX |
|---|
| Appendix 4C - June 2018 quarter | Jul 27, 2018 | Quarterly report | ASX |
|---|
| Photosoft efficiently destroys ovarian cancer cells in vitro | Jul 4, 2018 | Other filings | ASX |
|---|
| Appendix 4C - March 2018 quarter | Apr 25, 2018 | Quarterly report | ASX |
|---|
| Invion alliance with Hudson Institute of Medical Research | Mar 19, 2018 | Other filings | ASX |
|---|
| Completion iof Rights Issue | Mar 13, 2018 | Financing | ASX |
|---|
| Appendix 4D and Financial Report for half year to 31 Dec 17 | Feb 27, 2018 | Interim report | ASX |
|---|
| Rights Issue Information Booklet | Feb 11, 2018 | Financing | ASX |
|---|
| Appendix 4C - December 2017 Quarter | Jan 28, 2018 | Quarterly report | ASX |
|---|
| Appointment of Non Executive Director and Chairman | Nov 30, 2017 | Management or board change | ASX |
|---|
| AGM - Withdrawal of Resolution prior to Meeting | Nov 29, 2017 | Other filings | ASX |
|---|
| AGM Notice of Meeting And Proxy Form | Oct 29, 2017 | Meeting notice | ASX |
|---|
| Appendix 4C - cashflow statement for the September quarter | Oct 27, 2017 | Quarterly report | ASX |
|---|
| Appendix 4G - Key to governance disclosures | Oct 26, 2017 | Other filings | ASX |
|---|
| Strategic Transaction Update | Sep 5, 2017 | Other filings | ASX |
|---|
| Appendix 4E and Full Year Statutory Accounts | Aug 31, 2017 | Annual report | ASX |
|---|
| Appendix 4C - quarterly | Jul 30, 2017 | Quarterly report | ASX |
|---|
| Invion announces strategic alliance | Apr 18, 2017 | Other filings | ASX |
|---|
| Appendix 4D and Financial Report for half year to 31 Dec 16 | Feb 27, 2017 | Interim report | ASX |
|---|
| Appendix 4C December quarter | Jan 30, 2017 | Quarterly report | ASX |
|---|
| Appendix 4C for the September quarter | Oct 30, 2016 | Quarterly report | ASX |
|---|
| Receipt of R&T tax rebate | Sep 12, 2016 | Other filings | ASX |
|---|
| App 4E, Annual and Financial Report FY2016 | Aug 30, 2016 | Other filings | ASX |
|---|
| Response to ASX Appendix 4C query | Aug 8, 2016 | Explanation request | ASX |
|---|
| Phase 2 data presented to American Thoracic Society | May 20, 2016 | Other filings | ASX |
|---|
| End of Phase 2 Meeting for INV102 (nadolol) | Apr 3, 2016 | Other filings | ASX |
|---|
| Invion announces no secondary capital raise | Mar 30, 2016 | Other filings | ASX |
|---|
| Smoking cessation patent allowance and Operational update | Mar 10, 2016 | Other filings | ASX |
|---|
| Appendix 4D and Half Year Accounts | Feb 26, 2016 | Interim report | ASX |
|---|
| Invion completes SPP and Placement | Feb 11, 2016 | Financing | ASX |
|---|
| Smoking cessation trial results of ongoing data analysis | Feb 10, 2016 | Other filings | ASX |
|---|